GleamWall
中文EN

CRSP CRISPR Therapeutics AG

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1674416 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-34.3%
TTM net income YoY6.6%
TTM EPS YoY14.6%
Revenue 3-yr CAGR-47.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,114.8%
Net margin-1,812.1%
FCF margin-1,496.6%
EBITDA margin-2,041.3%

Returns

ROE-25.6%
ROA-19.0%
ROIC (approx.)-22.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets35.5%
Debt / equity0.36x
Current ratio16.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue8.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$12.67M$10.18M$1.46M$864,000$889,000$892,000$865,000$35.69M
R&D expense$71.89M$67.15M$68.57M$83.53M$58.90M$69.89M$72.48M$82.16M
SG&A expense$17.87M$17.55M$17.18M$18.40M$16.93M$18.92M$19.30M$18.12M
Operating income-$130.04M-$117.27M-$130.25M-$154.76M-$132.06M-$229.32M-$148.42M-$64.59M
Interest expense$3.33M$3.32M$553,000—$0$0$0—
Pretax income-$111.36M-$90.19M-$122.09M-$130.00M-$105.82M-$207.26M-$134.89M-$36.61M
Income tax$74,000$960,000$839,000$614,000$619,000$1.29M$1.11M$700,000
Net income-$111.44M-$91.15M-$122.93M-$130.61M-$106.44M-$208.55M-$136.00M-$37.31M
EBITDA-$125.84M-$112.97M-$125.93M-$149.10M-$127.66M-$224.72M-$143.69M-$59.75M
EPS (basic)-1.15-0.94-1.28—-1.17-2.40-1.58—
EPS (diluted)-1.15-0.94-1.28—-1.17-2.40-1.58—
Weighted avg. shares (diluted)96.74M96.51M96.05M—91.31M87.07M85.94M—
Balance sheet
Cash & equivalents$192.03M$291.34M$423.31M$347.56M$286.50M$193.62M$235.18M$298.26M
Short-term investments$2.08B$2.07B$2.02B$1.63B$1.63B$1.53B$1.62B$1.61B
Receivables———$0$0$0$0$25.00M
Current assets$2.29B$2.37B$2.45B$1.99B$1.93B$1.73B$1.87B$1.94B
PP&E, net$104.30M$108.07M$112.17M$115.85M$120.83M$124.93M$129.43M$134.09M
Intangibles———————$0
Total assets$2.56B$2.65B$2.73B$2.27B$2.25B$2.03B$2.17B$2.24B
Current liabilities$140.96M$132.90M$136.29M$149.12M$118.96M$104.36M$119.45M$87.78M
Long-term debt$586.93M$586.20M$585.47M$0————
Total debt$586.93M$586.20M$585.47M$0————
Total liabilities$908.34M$904.22M$911.26M$343.43M$329.33M$318.59M$336.94M$309.95M
Shareholders' equity$1.65B$1.75B$1.81B$1.92B$1.92B$1.71B$1.83B$1.93B
Net debt$394.91M$294.86M$162.16M-$347.56M————
Shares outstanding96.86M96.66M96.39M95.89M93.87M88.38M86.36M85.74M
Cash flow statement
Operating cash flow-$89.68M-$83.50M-$108.90M-$92.55M-$84.63M-$113.88M-$53.95M-$50.03M
Capital expenditure$414,000$648,000$504,000$517,000$74,000$117,000$206,000$254,000
Free cash flow-$90.10M-$84.15M-$109.40M-$93.07M-$84.71M-$114.00M-$54.15M-$50.28M
Investing cash flow-$14.09M-$55.66M-$410.74M$37.20M-$119.23M$69.98M-$19.75M$105.83M
Financing cash flow$4.45M$7.18M$591.91M$116.41M$296.77M$2.26M$10.59M$16.88M
Depreciation & amortization$4.20M$4.30M$4.32M$5.66M$4.40M$4.60M$4.74M$4.84M
Stock-based compensation$17.96M$17.32M$16.32M$18.08M$16.60M$17.61M$20.21M$21.95M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.